The finding that niclosamide inhibits S100A4-driven metastasis triggers a phase II clinical trial (ClinicalTrial.gov registration number: NCT02519582) to evaluate its safety and efficacy in metastatic colorectal cancer [18,19]. The gene discussed is S100A4; the disease is metastatic colorectal cancer.